- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04613804
Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy
November 1, 2020 updated by: Fujian Cancer Hospital
Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy :a Single-arm Phase II Trial
Lung cancer is the malignant tumor with the highest incidence and mortality in China.
Non-small cell lung cancer (NSCLC) ,which includes non-squamous cell carcinoma (including adenocarcinoma, large cell carcinoma, and other cell types) and squamous cell carcinoma, accounts for about 80% of lung cancer.
Platinum-based two-drug chemotherapy is the first-line standard treatment for driver-gene negative advanced NSCLC, but most patients experience disease progression after 4 to 6 months.
To extend the efficacy of first-line treatment, maintenance therapy is a logical clinical option for patients who are effective after 4 to 6 cycles of standard treatment.
There is currently no standard regimen for maintenance treatment of NSCLC.
We evaluated the effectiveness and safety of maintenance therapy with the anti-PD-1 monoclonal antibody (Toripalimab injection) followed by the first-line standard regimen in advanced NSCLC patients who are effective after standard treatment.
With a view to exploring treatment methods that are effective for the maintenance treatment of driver-gene negative advanced NSCLC and have little toxic and side effects,thereby improving the survival prognosis of these patients.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
Platinum-based two-drug chemotherapy is the first-line standard treatment for driver-negative advanced NSCLC, but most patients experience disease progression after 4 to 6 months.
To extend the efficacy of first-line treatment, maintenance therapy is a logical clinical option for patients who are effective after 4 to 6 cycles of standard treatment.
There is currently no standard regimen for maintenance treatment of NSCLC.
We evaluated the effectiveness and safety of the anti-PD-1 monoclonal antibody (Toripalimab injection) followed by maintenance therapy in advanced NSCLC that was effective in the first-line standard regimen.Thereby improving the survival prognosis of advanced NSCLC.
Study Type
Interventional
Enrollment (Anticipated)
30
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Fujian
-
Fuzhou, Fujian, China
- Fujian Cancer Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Criteria:
Inclusion Criteria:
- Fully understand the research and voluntarily sign the informed consent form (ICF)
- Age 18 to 75 years
- Histological or cytological documentation of non-small cell lung cance.
- Diagnosed as stage IV by imaging (staging according to AJCC eighth edition).
- Gene test is negative for EGFR, ALK, ROS1 confirmed by molecular pathology (tissue, ARMS method or NGS).
- Previously received first-line standard chemotherapy for non-small cell lung cancer (platinum combined with third-generation chemotherapy drugs in a two-drug combination regimen: pemetrexed or paclitaxel or docetaxel or gemcitabine or vinorelbine combined with cisplatin or carboplatin), and which were assessed the effectiveness by imaging(SD, PR or CR).
- At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria measured within 4 weeks prior to registration.
- ECOG performance status 0-1
- Expected overall survival time≥3 months
Adequate bone marrow, Coagulation function,hepatic and renal function should be assessed by the following laboratory requirements conducted within 7 days before starting study treatment:
- Leukocytes ≥ 3.0 x109/ L, absolute neutrophil count (ANC) ≥ 1.5 x109/ L, platelet count ≥ 100 x109/ L, hemoglobin (Hb) ≥9g/ dL.
- Total bilirubin ≤ 1.5 x the upper limit of normal (ULN).
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x ULN.
- Serum creatinine ≤ 1.5 x the ULN.
- Calculated creatinine clearance or 24 hour creatinine clearance ≥ 40 mL/ min.
- INR≤1.5, Activated partial thromboplastin time(APTT)≤1.5×ULN.
- Patients with hepatitis B virus (HBV) infection and inactive/asymptomatic HBV carriers, or patients with chronic or active HBV, if the HBV DNA is <500IU/ml, or 2500copies/ml at the time of screening,can enter the group.
- Male subjects and women of childbearing age must have contraception within 24 weeks from the start of the study to the last time of using the drug.
Exclusion Criteria:
- Tumor histology or cytology pathology confirmed with small cell lung cancer components or sarcomatoid lesions.
- Previously received any T-cell co-stimulation or immune checkpoint therapy, including but not limited to CTLA-4 inhibitors, PD-1 inhibitors, PD-L1 / 2 inhibitors or other drugs that target T cells.
- Major autoimmune diseases.
- Subjects who were vaccinated or planned to be vaccinated within 4 weeks before the first time using the study drug.
- LD, drug-induced pneumonia, radiation pneumonitis requiring steroid therapy, or clinically active pneumonia or severe pulmonary dysfunction.
- TB or subjects with a history of active tuberculosis infection ≤ 48 weeks before screening, whether or not treated.
- Symptomatic cardiac disease, such as: heart failure above NYHA level 2, unstable angina pectoris, myocardial infarction occurred within 24 weeks, clinically significant supraventricular or ventricular arrhythmias require treatment or intervention.
- Acquired immunosuppression (AIDS or major immunosuppressive agents)
- Suffering from active viral hepatitis. Defined as: Hepatitis B virus (HBV) infection and HBV DNA ≥ 2500 copies / ml; or Hepatitis C virus (HCV) infection (quantitative test results of anti-HCV positive and HCV RNA are greater than the lower limit of detection) .
- Mental illness, alcohol, drug or substance abuse
- Pregnant or lactating women.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Toripalimab group
Toripalimab 240mg ivgtt Q21d
|
Qualified subjects will be treated with "toripalimab 240mg q21d" as a treatment cycle.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival (PFS)
Time Frame: up to 12 months
|
PFS by investigator-reported measurements according to CT image.
PFS was calculated from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months.PD was defined as Overall Response by RECIST criteria v1.1 according to CT image.
|
up to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival time
Time Frame: Up to 36 months
|
OS was calculated from the date of randomization to death from any cause.
|
Up to 36 months
|
Objective response rate
Time Frame: up to 12 months
|
CR + PR rate according to the RECIST version 1.1 guidelines.
|
up to 12 months
|
Disease control rate
Time Frame: up to 12 months
|
CR + PR + SD rate according to the RECIST version 1.1 guidelines.
|
up to 12 months
|
Adverse events rate
Time Frame: up to 12 months
|
Adverse events were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.
|
up to 12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in immune environment
Time Frame: up to 12 months
|
Assess the expression of PD-1, PD-L1, and TILs in tumor tissues before and after first-line standard chemotherapy
|
up to 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Zhiyong He, master, Fujian Cancer Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
December 1, 2020
Primary Completion (Anticipated)
November 30, 2022
Study Completion (Anticipated)
November 30, 2023
Study Registration Dates
First Submitted
September 5, 2020
First Submitted That Met QC Criteria
November 1, 2020
First Posted (Actual)
November 3, 2020
Study Record Updates
Last Update Posted (Actual)
November 3, 2020
Last Update Submitted That Met QC Criteria
November 1, 2020
Last Verified
September 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Immune Checkpoint Inhibitors
Other Study ID Numbers
- SCOG001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on NSCLC Stage IV
-
Fondazione Policlinico Universitario Agostino Gemelli...Completed
-
Spanish Lung Cancer GroupCompleted
-
Niguarda HospitalUniversity of Turin, Italy; Fondazione del Piemonte per l'OncologiaCompleted
-
Mylan Pharmaceuticals IncCompletedNSCLC Stage IVTurkey, Taiwan, Vietnam, Croatia, India, Russian Federation, Spain, Hungary, Bosnia and Herzegovina, Ukraine, Poland, Romania, Belarus, Bulgaria, Georgia, Italy, Philippines
-
Instituto do Cancer do Estado de São PauloUnknown
-
Xiaorong DongUnknownHealthy Subjects | NSCLC Stage IV | NSCLC, Stage III | NSCLC, Stage I | NSCLC, Stage IIChina
-
Microbio Co LtdRecruiting
-
The Netherlands Cancer InstituteBristol-Myers SquibbTerminated
-
Fudan UniversityUnknown
-
KangLaiTe USATerminatedStage IV NSCLCUnited States
Clinical Trials on Toripalimab Injection
-
Mabwell (Shanghai) Bioscience Co., Ltd.Not yet recruitingAdvanced Urothelial CarcinomaChina
-
Shanghai Junshi Bioscience Co., Ltd.Not yet recruitingMelanoma | Breast Cancer | Lung CanceChina
-
Shanghai Junshi Bioscience Co., Ltd.RecruitingLimited-stage Small Cell Lung Cancer (LS-SCLC)China, France, United States, Spain, Taiwan, Korea, Republic of, Turkey, Italy, Netherlands, Georgia, Germany, Belgium, Poland, Romania
-
RemeGen Co., Ltd.RecruitingAdvanced Solid TumorChina
-
Abbisko Therapeutics Co, LtdEnrolling by invitationTriple Negative Breast CancerChina
-
Nanjing Leads Biolabs Co.,LtdRecruitingAdvanced Solid TumorChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Recruiting
-
Beijing Friendship HospitalNot yet recruiting
-
Ascentage Pharma Group Inc.Recruiting
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdRecruitingAdvanced Hepatocellular CarcinomaChina